Gene Targets of CAR-T Cell Therapy for Glioblastoma
Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis following conventional therapeutic interventions. Moreover, the blood–brain barrier (BBB) severely impedes the permeation of chemotherapy drugs, thereby reducing their efficacy. Consequently, it is essential to develop nov...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/8/2351 |
| _version_ | 1797606067765510144 |
|---|---|
| author | Chaoqun Wang Yuntao Li Lijuan Gu Ran Chen Hua Zhu Xu Zhang Yonggang Zhang Shi Feng Sheng Qiu Zhihong Jian Xiaoxing Xiong |
| author_facet | Chaoqun Wang Yuntao Li Lijuan Gu Ran Chen Hua Zhu Xu Zhang Yonggang Zhang Shi Feng Sheng Qiu Zhihong Jian Xiaoxing Xiong |
| author_sort | Chaoqun Wang |
| collection | DOAJ |
| description | Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis following conventional therapeutic interventions. Moreover, the blood–brain barrier (BBB) severely impedes the permeation of chemotherapy drugs, thereby reducing their efficacy. Consequently, it is essential to develop novel GBM treatment methods. A novel kind of pericyte immunotherapy known as chimeric antigen receptor T (CAR-T) cell treatment uses CAR-T cells to target and destroy tumor cells without the aid of the antigen with great specificity and in a manner that is not major histocompatibility complex (MHC)-restricted. It has emerged as one of the most promising therapy techniques with positive clinical outcomes in hematological cancers, particularly leukemia. Due to its efficacy in hematologic cancers, CAR-T cell therapy could potentially treat solid tumors, including GBM. On the other hand, CAR-T cell treatment has not been as therapeutically effective in treating GBM as it has in treating other hematologic malignancies. CAR-T cell treatments for GBM have several challenges. This paper reviewed the use of CAR-T cell therapy in hematologic tumors and the selection of targets, difficulties, and challenges in GBM. |
| first_indexed | 2024-03-11T05:10:07Z |
| format | Article |
| id | doaj.art-736539f0bc2b4ac98d60673edeab9b1e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:10:07Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-736539f0bc2b4ac98d60673edeab9b1e2023-11-17T18:39:47ZengMDPI AGCancers2072-66942023-04-01158235110.3390/cancers15082351Gene Targets of CAR-T Cell Therapy for GlioblastomaChaoqun Wang0Yuntao Li1Lijuan Gu2Ran Chen3Hua Zhu4Xu Zhang5Yonggang Zhang6Shi Feng7Sheng Qiu8Zhihong Jian9Xiaoxing Xiong10Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaCentral Laboratory, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Neurosurgery, Huzhou Central Hospital, Affiliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou 310009, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaGlioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis following conventional therapeutic interventions. Moreover, the blood–brain barrier (BBB) severely impedes the permeation of chemotherapy drugs, thereby reducing their efficacy. Consequently, it is essential to develop novel GBM treatment methods. A novel kind of pericyte immunotherapy known as chimeric antigen receptor T (CAR-T) cell treatment uses CAR-T cells to target and destroy tumor cells without the aid of the antigen with great specificity and in a manner that is not major histocompatibility complex (MHC)-restricted. It has emerged as one of the most promising therapy techniques with positive clinical outcomes in hematological cancers, particularly leukemia. Due to its efficacy in hematologic cancers, CAR-T cell therapy could potentially treat solid tumors, including GBM. On the other hand, CAR-T cell treatment has not been as therapeutically effective in treating GBM as it has in treating other hematologic malignancies. CAR-T cell treatments for GBM have several challenges. This paper reviewed the use of CAR-T cell therapy in hematologic tumors and the selection of targets, difficulties, and challenges in GBM.https://www.mdpi.com/2072-6694/15/8/2351CAR-Tglioblastomatargetchimeric antigen receptor T-cell immunotherapy |
| spellingShingle | Chaoqun Wang Yuntao Li Lijuan Gu Ran Chen Hua Zhu Xu Zhang Yonggang Zhang Shi Feng Sheng Qiu Zhihong Jian Xiaoxing Xiong Gene Targets of CAR-T Cell Therapy for Glioblastoma Cancers CAR-T glioblastoma target chimeric antigen receptor T-cell immunotherapy |
| title | Gene Targets of CAR-T Cell Therapy for Glioblastoma |
| title_full | Gene Targets of CAR-T Cell Therapy for Glioblastoma |
| title_fullStr | Gene Targets of CAR-T Cell Therapy for Glioblastoma |
| title_full_unstemmed | Gene Targets of CAR-T Cell Therapy for Glioblastoma |
| title_short | Gene Targets of CAR-T Cell Therapy for Glioblastoma |
| title_sort | gene targets of car t cell therapy for glioblastoma |
| topic | CAR-T glioblastoma target chimeric antigen receptor T-cell immunotherapy |
| url | https://www.mdpi.com/2072-6694/15/8/2351 |
| work_keys_str_mv | AT chaoqunwang genetargetsofcartcelltherapyforglioblastoma AT yuntaoli genetargetsofcartcelltherapyforglioblastoma AT lijuangu genetargetsofcartcelltherapyforglioblastoma AT ranchen genetargetsofcartcelltherapyforglioblastoma AT huazhu genetargetsofcartcelltherapyforglioblastoma AT xuzhang genetargetsofcartcelltherapyforglioblastoma AT yonggangzhang genetargetsofcartcelltherapyforglioblastoma AT shifeng genetargetsofcartcelltherapyforglioblastoma AT shengqiu genetargetsofcartcelltherapyforglioblastoma AT zhihongjian genetargetsofcartcelltherapyforglioblastoma AT xiaoxingxiong genetargetsofcartcelltherapyforglioblastoma |